Tyra Bio - TYRA Quarterly EPS earnings growth

Corporate company logo of Tyra Biosciences (TYRA)

Tyra Biosciences, Inc. (TYRA) is currently burning capital on costly research without current sales. Quarterly net income per share dynamics demonstrate a market imbalance, where the -47.90 metric serves as the target level. Prospects rely on the success of the TYRA-300 drug and fund support, however, geopolitical strife and sanctions seriously hinder international biomaterial logistics and the execution of global trials.

tyra.bio (TYRA) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 11/17/2026

Analytical breakdowns for Tyra Biosciences, Inc.

- share price and consensus valuation forecast:
Fundamental company valuation:tyra.bio - TYRA
Flagship merchandise of tyra.bio

Quarterly EPS growth measures the dynamics of net income per share, filtering out market noise to assess real profitability. Investors analyze this metric to verify the sustainability of the business's cash flows. By studying the growth rates of quarterly net income per share, one can detect liquidity shortages in advance. For Tyra Biosciences, Inc. (TYRA), this metric reflects the efficiency of investments in precision oncology. Innovative molecular design must convert into stable financial strengthening for the company.

Analysis of competing companies

GMAB (Genmab) - Year-over-year net earnings per share growth for the last 12 months|EXEL: Year-over-year earnings per share growth rate for the last twelve months|NUVL (Nuvalent Therapeutics) - Quarterly EPS earnings growth|Quarterly EPS earnings growth kymeratx.com|Year-over-year earnings per share growth for the last twelve months IDEAYA Biosciences, Inc. (IDYA)|ELVN (Enliven Therapeutics, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ORIC (ORIC Pharmaceuticals Inc)|Net earnings per share growth for the trailing year Relay Pharma|Nurix Therapeutics Inc - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Verastem|GLUE (Monte Rosa Therapeutics) - Year-over-year net earnings per share growth for the last 12 months|CGEM: Year-over-year earnings per share growth rate for the last twelve months|IMRX (immuneering.com) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months C4 Tx CCCC|Quarterly EPS earnings growth BDTX|Repare Therapeutics Inc. - Year-over-year earnings per share growth for the last 12 months|PMV Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months KPTI|PPCB: Year-over-year net earnings per share growth for the last 12 months|Cyclacel Pharmaceuticals - Year-over-year earnings per share growth rate for the last twelve months|AADI: Quarterly EPS earnings growth|Aileron Therapeutics Inc - Year-over-year earnings per one share growth for the last 12 months|BPMC (Blueprint Medicines Corp.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months glycomimetics.com GLYC|Year-over-year earnings per share growth for the last twelve months SpringWorks (SWTX)